

GP-1637
#18
4/21/98

Attorney Docket: NEX61/CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JANJIC *ET AL.*)
)
SERIAL NO.: 08/897,351)
)
FILED: JULY 21, 1997)
)
TITLE: VASCULAR ENDOTHELIAL)
GROWTH FACTOR (VEGF))
NUCLEIC ACID LIGAND)
COMPLEXES)

EXAMINER:

ART UNIT:

RECEIVED
MAY - 6 1998
MATRIX CUSTOMER
SERVICE CENTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patent listed on the attached Form PTO-1449, copy enclosed, which may be material to examination of the above-identified application.

TIME OF TRANSMITTAL

This Supplemental Information Disclosure Statement is being filed *within* three months of the filing date of the application or date of entry into the national stage of an international application as set forth in §1.491 or before the mailing date of a first Office Action on the merits under §1.97(b), whichever event occurs last.

No fee is believed to be due in this instance, however the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 22-0277.

37 CFR 1.8


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on April 28, 1998

Signature: Mary Ann Holland
Name: Mary Ann Holland

The filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner. The listed patents and publications are believed of interest herein and consideration and citation as of interest by Examiner is respectfully requested.

Respectfully submitted,


Rosemary Kellogg, #39,726
Swanson & Bratschun, L.L.C.
8400 E. Prentice Ave., Suite 200
Englewood, CO 80111
Telephone: (303) 793-3333

cc: V. Appleby

C:\WPDOCS\NEXAGEN\NEX61CIP\supids2 doc.wpd /mah